John Hunter Peel Alexander, MD

Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail 200 Morris Street, Durham, NC 27701
Phone (919) 668-8955
Email address john.h.alexander@duke.edu

John H. Alexander, MD, MHS is a cardiologist and Professor of Medicine in the Department of Medicine, Division of Cardiology at Duke University School of Medicine, as well as the Vice Chief, Clinical Research in the Division of Cardiology. He is the Director of Cardiovascular Research at the Duke Clinical Research Institute where he oversees a large group of clinical research faculty and a broad portfolio of cardiovascular clinical trials and observational clinical research programs. He is a member of the American Society of Clinical Investigation.

Dr. Alexander’s clinical interests are in acute and general cardiovascular disease, valvular heart disease, and echocardiology. His research is focused on the translation of novel therapeutic concepts into clinical data through clinical trials, specifically on the therapeutics of acute coronary syndromes, chronic coronary artery disease, and cardiac surgery and on novel methodological approaches to clinical trials. He was on the Executive Committee of the ARISTOTLE trial of apixaban in patients with atrial fibrillation and was the Principal Investigator of the APPRAISE-2 trial of apixaban in patients with acute coronary syndromes.

Dr. Alexander has published extensively and has served as the principal investigator of numerous multicenter clinical trials. He currently serves as the co-chair of the Clinical Trial Transformation Initiative (CTTI).

Education and Training

  • Fellow in Cardiology, Medicine, Duke University, 1996 - 2000
  • Medical Resident, Medicine, Children's Hospital Boston, 1993 - 1996
  • M.D., University of Pennsylvania, 1993

Publications

Diepen, Sean van, Rajendra H. Mehta, Jeffrey D. Leimberger, Shaun G. Goodman, Stephen Fremes, Rachael Jankowich, Matthias Heringlake, et al. “Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery.” J Thorac Cardiovasc Surg 159, no. 6 (June 2020): 2302-2309.e6. https://doi.org/10.1016/j.jtcvs.2019.06.020.

PMID
31358329
Full Text

Alexander, John H., Daniel Wojdyla, Amit N. Vora, Laine Thomas, Christopher B. Granger, Shaun G. Goodman, Ronald Aronson, Stephan Windecker, Roxana Mehran, and Renato D. Lopes. “Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.” Circulation 141, no. 20 (May 19, 2020): 1618–27. https://doi.org/10.1161/CIRCULATIONAHA.120.046534.

PMID
32223444
Full Text

Lopes, Renato D., Ariane Vieira Scarlatelli Macedo, Pedro Gabriel Melo de Barros E Silva, Renata Junqueira Moll-Bernardes, Andre Feldman, Guilherme D’Andréa Saba Arruda, Andrea Silvestre de Souza, et al. “Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).” Am Heart J, May 13, 2020. https://doi.org/10.1016/j.ahj.2020.05.002.

PMID
32405071
Full Text

Lopes, Renato D., Hwanhee Hong, Ralf E. Harskamp, Deepak L. Bhatt, Roxana Mehran, Christopher P. Cannon, Christopher B. Granger, et al. “Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis.” Jama Cardiol 5, no. 5 (May 1, 2020): 582–89. https://doi.org/10.1001/jamacardio.2019.6175.

PMID
32101251
Full Text

Marquis-Gravel, Guillaume, Zhen Huang, Steven L. Zelenkofske, A Michael Lincoff, Roxana Mehran, P Gabriel Steg, Christoph Bode, John H. Alexander, and Thomas J. Povsic. “Interplay between PCI access site, anticoagulant agent, and bleeding: Insights from the REGULATE-PCI randomized trial.” Am Heart J 223 (May 2020): 84–86. https://doi.org/10.1016/j.ahj.2020.02.013.

PMID
32199152
Full Text

Stanifer, John W., Sean D. Pokorney, Glenn M. Chertow, Stefan H. Hohnloser, Daniel M. Wojdyla, Samira Garonzik, Wonkyung Byon, et al. “Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease.” Circulation 141, no. 17 (April 28, 2020): 1384–92. https://doi.org/10.1161/CIRCULATIONAHA.119.044059.

PMID
32160801
Full Text

Inagaki, Nobuya, Wenying Yang, Hirotaka Watada, Linong Ji, Sven Schnaidt, Egon Pfarr, Tomoo Okamura, et al. “Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial.” Diabetol Int 11, no. 2 (April 2020): 129–41. https://doi.org/10.1007/s13340-019-00412-x.

PMID
32206483
Full Text

Zeitouni, Michel, Anna Giczewska, Renato D. Lopes, Daniel M. Wojdyla, Christina Christersson, Agneta Siegbahn, Raffaele De Caterina, et al. “Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial.” J Am Coll Cardiol 75, no. 10 (March 17, 2020): 1145–55. https://doi.org/10.1016/j.jacc.2019.12.060.

PMID
32164888
Full Text

Lopes, Renato D., Sergio Leonardi, Daniel M. Wojdyla, Amit N. Vora, Laine Thomas, Robert F. Storey, Dragos Vinereanu, et al. “Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial.” Circulation 141, no. 9 (March 3, 2020): 781–83. https://doi.org/10.1161/CIRCULATIONAHA.119.044584.

PMID
31707833
Full Text

Pages